A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects

Trial Profile

A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Lanadelumab (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Dyax; Shire
  • Most Recent Events

    • 23 Feb 2017 Results published in a Shire media release.
    • 23 Feb 2017 Primary endpoint (The number of attacks of angioedema per week) has been met.
    • 23 Feb 2017 Results assessing safety and efficacy of Lanadelumab, published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top